Nexavar® Versus Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer

Mise à jour : Il y a 4 ans
Référence : NCT00984282

Femme et Homme

Extrait

Trial of sorafenib versus placebo in the treatment of locally advanced or metastatic differentiated thyroid cancer refractory to radioiodine


Critère d'inclusion

  • Thyroid Neoplasms


Liens